Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

NCT06170216 ·Status: ACTIVE_NOT_RECRUITING

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

NCT04245839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

NCT02856646 ·Status: COMPLETED

A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL).

NCT00301314 ·Status: COMPLETED

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

NCT04134325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1

Radiation Free Chemotherapy for Early Hodgkin Lymphoma

NCT04866654 ·Status: RECRUITING ·Phase: PHASE2

Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)

NCT02038946 ·Status: COMPLETED ·Phase: PHASE2

Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

NCT00816959 ·Status: UNKNOWN ·Phase: PHASE3

Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance

NCT03311958 ·Status: COMPLETED ·Phase: EARLY_PHASE1

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

NCT01461928 ·Status: COMPLETED ·Phase: PHASE3

Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma

NCT03602131 ·Status: UNKNOWN ·Phase: PHASE2

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

NCT00003204 ·Status: COMPLETED ·Phase: PHASE3

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

NCT03366272 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

NCT02164500 ·Status: COMPLETED ·Phase: PHASE2

Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)

NCT05976997 ·Status: RECRUITING ·Phase: PHASE2

IMPACT Non Hodgkins Lymphoma (NHL) Study

NCT00903812 ·Status: COMPLETED

Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

NCT03920631 ·Status: WITHDRAWN ·Phase: PHASE1

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

NCT03586999 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

NCT00186394 ·Status: COMPLETED ·Phase: PHASE2

Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above

NCT05404945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma

NCT01130194 ·Status: COMPLETED ·Phase: PHASE2

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

NCT05900765 ·Status: RECRUITING ·Phase: PHASE2

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

NCT02631746 ·Status: COMPLETED ·Phase: PHASE2

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

NCT00398177 ·Status: RECRUITING